The company reported core earnings per share of $2.79, beating expectations of $2.62, according to Bloomberg.
Revenue came in at $16.2 billion, compared with expectations of $15.98 billion.
“With several potential blockbusters in late-stage development and transformative technologies rapidly scaling up, we are well positioned to deliver on our 2030 ambition and sustain growth over the next decade,” AstraZeneca CEO Pascal Soriot writes in the report.
